Xiamen Spacegen Co., Ltd., Xiamen (2025)

10/09/2025

Over the past 40 years, small cell lung cancer (SCLC) has been a clinical "hard nut to crack", with almost no options left after chemotherapy resistance.

Now, a major review in Nature Cancer brings six breakthrough directions, offering the first glimpse of the possibility of being besieged by "curative-level" therapies for this "incurable disease". SCLC has finally entered the "treatment explosion" era!

The treatment of SCLC is shifting from "laboratory to clinical" to "bedside back to laboratory" reverse translation: circulating clinical observations, deep omics, tissue banks and rapid autopsy results back to the laboratory to drive hypothesis validation and target discovery; while using surface omics, ADC/TCE new drugs, rational combination regimens, limiting phenotypic plasticity and epigenetic intervention to counter heterogeneity and resistance; moving the battle line forward through smoking cessation, early screening and circulating biomarkers; and solving the obstacles of age, comorbidities and economic accessibility in the real world to truly implement innovative therapies.

Original Article Express：www.sspacegen.com

08/09/2025

Have you ever wondered why cancer seems to be particularly prevalent in some families? In fact, about 5% to 10% of tumors are closely related to genetic factors. With the development of genetic testing technology, we can now uncover the secrets hidden in DNA. Genetic testing is not fortune-telling but a science. It gives us an unprecedented ability to predict risks and proactively manage our health. Understanding the genetic susceptibility to gynecological tumors, through scientific genetic testing and professional genetic counseling, can help high-risk individuals (whether patients or healthy carriers) detect risks earlier, treat tumors more precisely, prevent related cancers more effectively, and guide scientific family planning. This is not only an active management of personal health but also a responsibility towards the health of family members. If you meet the risk factors mentioned in the text, it is recommended to consult a doctor or genetic counselor to assess the necessity of genetic susceptibility testing.

Original Article Express：www.sspacegen.com

04/09/2025

Although the incidence and mortality rates of leukemia have decreased significantly worldwide over the past 50 years, leukemia remains a global health challenge, being the 13th most common cancer and the 10th leading cause of cancer-related deaths globally.

Each year, hundreds of thousands are affected, highlighting the urgent need for awareness, early detection, and innovative treatments.

At spacegen, we’re working to change the landscape of Leukemia treatment through precision oncology. By analyzing each patient’s unique genetic and molecular profile, we help clinicians personalize treatment plans, ensuring the best possible care for Leukemia patients.

This , let’s come together to raise awareness, support those affected, and continue pushing for better diagnostic tools and treatments.

03/09/2025

On August 22, 2025, the National Medical Products Administration (NMPA) of China approved the marketing of datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo, for the treatment of adult patients with unresectable or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer who have received endocrine therapy and at least one line of advanced chemotherapy. This approval offers a new option for patients with drug-resistant disease in this subtype.

This approval is based on the results of the global Phase III TROPION-Breast01 study: Compared with chemotherapy, datopotamab deruxtecan significantly reduced the risk of disease progression or death by 37%, and the median progression-free survival (mPFS) was extended to 6.9 months (4.9 months in the chemotherapy group). Data from the Chinese subgroup showed that the median PFS reached 8.1 months, nearly twice that of the chemotherapy group (4.2 months). HR+/HER2- breast cancer accounts for 70% of all breast cancers. Patients often face drug resistance after endocrine therapy and chemotherapy. As Daiichi Sankyo's second ADC drug approved in China after Enhertu for breast cancer, datopotamab deruxtecan will fill the unmet clinical needs.

Original Article Express：www.sspacegen.com

01/09/2025

In today's era of precision oncology, genetic testing not only deciphers the genetic code of cancer cells but also directly influences treatment outcomes and patient survival. Two recent studies have comprehensively confirmed the "hardcore strength" of NGS in lung cancer treatment, from clinical efficacy to detection performance.

NGS is not a "black technology" in the laboratory for a long time, but a "clinical sharp weapon" that can effectively change the fate of lung cancer patients—it enables more accurate detection, more efficient treatment, and more and more patients to see the hope of long-term survival.

Original Article Express：www.sspacegen.com

25/08/2025

This weekend, we are delighted to interact and exchange insights with top medical experts from home and abroad. This event provides a platform for us to showcase to the participants how SpaceGen's "Comprehensive Solution for Tumor Full-Process Management" shapes the future of precision diagnosis and treatment.

We are honored to present and deliver an insightful speech titled "The Application of Genetic Testing in Gynecological Tumors" at the China Precision Medical Industry Expo and China Precision Medical Conference 2025, focusing on the diagnosis and treatment research of gynecological tumors such as uterine tumors, ovarian cancer, and cervical cancer.

We are particularly grateful to the organizers of this conference for inviting us to share our insights on advancing molecular diagnostics in oncology. Our team is honored to contribute to the global impact of precision oncology through continuous dialogue and exploration of technological innovations in molecular diagnostics.

22/08/2025

Welcome to the first day of ! Join us at booth A87 to discover Spacegen's one-step IVD solution. We will bring about our latest innovations to meet your evolving needs and become your trusted golbal partner. Don't miss this opportunity in , we are looking forword to meeting you personally here!

21/08/2025

Epigenetic dysregulation orchestrates endocrine resistance in hormone-receptor-positive (HR⁺) breast cancer through three master mechanisms—DNA methylation, histone post-translational modification, and non-coding RNA interference. Overexpression of the histone demethylase KDM5B and histone deacetylases (HDACs) transcriptionally silences estrogen receptor (ER) expression, whereas the isoform-selective HDAC inhibitor tucidinostat—now approved in combination with aromatase inhibitors—reinstates endocrine sensitivity. Concurrently, oncomiRs such as miR-221/222 extinguish ERα translation, yet miRNA “sponge” constructs can resurrect tamoxifen responsiveness. These mechanistic insights are rapidly crystallizing into precision-guided, sequential therapeutic paradigms leveraging CDK4/6 and HDAC blockade, thereby illuminating an elegant new route to conquer endocrine resistance.

Original Article Express：www.sspacegen.com

14/08/2025

Lung cancer has reigned as the leading cause of cancer-related deaths across the globe for ten consecutive years, claiming the lives of approximately three to four individuals every single minute. Yet, the dawn of molecular marker-based targeted therapies is reshaping this grim landscape. Through the precision of biomarker testing, clinicians are now empowered to detect specific genetic mutations within a patient’s tumor, paving the way for tailored treatment strategies that significantly enhance both survival prospects and overall quality of life.

🎯 The EGFR molecular mutation stands at the forefront as the most prevalent genetic driver of lung cancer.

SpaceGen, our mission is to engineer cutting-edge diagnostic solutions that meet the urgent demands of clinical practice. We serve as the discerning “eyes” of physicians, illuminating the hidden mutations within the genome. 🔍With relentless dedication, we strive to equip every patient with the vital tools necessary to fight lung cancer.

Powered by state-of-the-art PCR technology, our EGFR Gene Mutation Detection Kit offers🧬:

🔸Comprehensive coverage of all actionable mutations across exons 18 to 21 of the EGFR gene, encompassing not only the classic sensitive mutations but also the resistant T790M and the challenging 20 insertions.
🔸Exceptional sensitivity, capable of detecting mutations present at a mere 1% frequency within a 10 ng DNA sample.
🔸Integration with clinical trial data and drug development research, offering robust support for informed and optimized therapeutic decisions.
🔸A streamlined, pre-packaged closed-tube detection system built upon our proprietary PAP-ARMS® technology, enabling accurate results with just a single-step workflow.

📩For the complete product catalog or to explore more cooperation opportunities, feel free to contact us at spacegen@ispacegen.com.
🌍Welcome to visit the official website of SpaceGen for more information: www.sspacegen.com

12/08/2025

SpaceGen : We are honored to participate in the 【30th Congress of the Chinese Society and the 14th Annual Meeting of Chinese Pathologists】, where we will showcase our cutting-edge NGS-based tumor diagnostic solution. You are warmly invited to join us in exploring the new frontier of molecular diagnostics and witness the dawn of a revolutionary diagnostic ecosystem.

Visit us at Booth
Date: August 21–24, 2025
Location: Expo Center, Shanghai

We eagerly anticipate the opportunity to welcome you and engage in meaningful exchanges together.

08/08/2025

Did you know?🧬 The undeniable presence of tumor heterogeneity leads to remarkable variations among patients in terms of disease progression, therapeutic responsiveness, and prognostic outcomes. Delving deeply into the molecular biology of tumors empowers us to embrace revolutionary concepts such as "treating different diseases with the same therapy" or "treating the same disease with tailored approaches."

🔍 The Pan Solid Tumor Sequencing Panel Assay (175 genes) offers comprehensive coverage of genes with profound clinical relevance in the diagnosis and management of solid tumors.The Panel is designed to identify all classes of actionable Genomic alterations , including SNV，SNP, CNV, InDels, and Fusions, across a total of 175 cancer-related genes.Spanning across multiple dimensions—including the prediction of therapeutic efficacy for targeted agents, immunotherapies, and chemotherapeutic drugs, as well as assessments of toxicity, drug tolerance, resistance mechanisms, and the auxiliary diagnosis of hereditary cancers—this panel fully satisfies the diverse demands of clinical diagnostics and cutting-edge scientific research.

Employing a sophisticated combination of probe capture and next-generation sequencing (NGS) technologies, it is fully compatible with leading platforms such as BGI and Illumina. This advanced design ensures that it becomes the most dependable and precise diagnostic instrument within your laboratory.

🔬At SpaceGen, we are steadfastly committed to delivering innovative oncology diagnostic solutions that not only advance precision medicine but also profoundly contribute to the betterment of public health.

📩For the complete product catalog or to explore more cooperation opportunities, feel free to contact us at spacegen@ispacegen.com.
🌍Welcome to visit the official website of SpaceGen for more information: sspacegen.com

Xiamen Spacegen Co., Ltd.

10/09/2025

08/09/2025

04/09/2025

03/09/2025

01/09/2025

25/08/2025

22/08/2025

21/08/2025

14/08/2025

12/08/2025

08/08/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category